Payment overview · 2025
General Payments
$1,063.79
73 reported records · 12 companies
Healthcare provider profile · identity verified
Kent A Guisinger, DO
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, OH · NPI 1619955325
Verified facts
What the public records show
CMS Open Payments records show Kent A Guisinger, DO received $1,063.79 in general payments during 2025 across 73 reported records.
ABBVIE INC. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $282.32 | 26.5% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $269.79 | 25.4% | 17 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $152.82 | 14.4% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.60 | 7.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.58 | 6.2% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.08 | 4.2% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $35.88 | 3.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.14 | 3.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.69 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.86 | 2.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.42 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.61 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,063.79 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $280.31 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $204.34 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $171.52 | 11 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $152.82 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.00 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.15 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $35.88 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.69 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 129 |
| Omeprazole | Omeprazole | 290 | 83 |
| Gabapentin | Gabapentin | 279 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 68 |
| Lisinopril | Lisinopril | 213 | 60 |
| Alprazolam | Alprazolam | 186 | 24 |
| Metformin Hcl | Metformin Hcl | 180 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 40 |
| Losartan Potassium | Losartan Potassium | 121 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 33 |
| Potassium Chloride | Potassium Chloride | 112 | 31 |
| Meloxicam | Meloxicam | 103 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 42 |
| Azithromycin | Azithromycin | 102 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 96 | 11 |
| Furosemide | Furosemide | 86 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 74 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 32 |
| Allopurinol | Allopurinol | 70 | 21 |
| Prednisone | Prednisone | 67 | 43 |
| Lovastatin | Lovastatin | 66 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 18 |
| Simvastatin | Simvastatin | 60 | 18 |
| Eliquis | Apixaban | 59 | 13 |
| Carvedilol | Carvedilol | 55 | 15 |
| Spironolactone | Spironolactone | 55 | 13 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 15 |
| Bupropion Xl | Bupropion Hcl | 49 | 18 |
| Amoxicillin | Amoxicillin | 48 | 36 |
| Buspirone Hcl | Buspirone Hcl | 47 | 16 |
| Trazodone Hcl | Trazodone Hcl | 46 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 29 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 16 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Famotidine | Famotidine | 36 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Armour Thyroid | Thyroid,pork | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Nateglinide | Nateglinide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Etodolac | Etodolac | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,063.79 · 73 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, FARXIGA, Flector, JARDIANCE, Kerendia, Korlym, Licart, PAXLOVID, QULIPTA, SYNTHROID, Tirosint, UBRELVY, VOQUEZNA, Veozah, XYOSTED, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error